Sri Lanka's National Medicines Regulatory Authority (NMRA) on Saturday approved China's Sinopharm Covid-19 vaccine for emergency use in the island country.
According to State Minister of Production, Supply and Regulation of Pharmaceuticals Channa Jayasumana, this is the third Covid-19 vaccine to be approved in the country after the AstraZeneca and Russia's Sputnik V jabs, reports Xinhua news agency.
Earlier this month, General Manager of the State Pharmaceutical Corporation (SPC) Dinusha Dassanayake said the SPC had also made an application to the NMRA to clear China's Sinovac vaccine for emergency use.
Sri Lanka is in the midst of a mass inoculation program as it began inoculating all those above 30 years old in the urban Western Province from mid-February, after vaccinating frontline workers and health workers with the AstraZeneca doses.
Sri Lanka received AstraZeneca doses from India in January and February.
It also received 264,000 doses of the AstraZeneca vaccine under the World Health Organization-led COVAX facility which is being administered to those above the age of 60 years.
--IANS
ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)